{"id":39068,"date":"2017-03-23T00:00:00","date_gmt":"2017-03-22T23:00:00","guid":{"rendered":"http:\/\/www.pcb.ub.edu\/\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/"},"modified":"2020-11-16T16:22:30","modified_gmt":"2020-11-16T15:22:30","slug":"minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/","title":{"rendered":"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102"},"content":{"rendered":"<p>MIN-102 es un metabolito del pioglitazona y se dirige a la adrenoleucodistrofia ligada al\u00a0cromosoma X (X-ALD), una enfermedad rara neurodegenerativa cr\u00f3nica y\u00a0debilitante potencialmente mortal. Existen dos principales fenotipos cl\u00ednicos de X-ALD:\u00a0adrenomieloneuropat\u00eda (AMN), caracterizada por disfunci\u00f3n motora progresiva, y ALD\u00a0cerebral (cALD), caracterizada por una neuroinflamaci\u00f3n severa que conduce a una muerte\u00a0prematura. Actualmente, no hay tratamientos\u00a0farmacol\u00f3gicos para X-ALD. MIN-102 es el\u00a0\u00fanico producto en desarrollo para uso potencial en ambos fenotipos.<\/p>\n<p>El ensayo de fase 1 ha sido un estudio combinado de dosis \u00fanica y m\u00faltiple ascendente con\u00a0el objetivo de evaluar la farmacocin\u00e9tica, la seguridad y la tolerabilidad del MIN-\u00a0102 en voluntarios sanos. Adem\u00e1s, el ensayo incluy\u00f3 la evaluaci\u00f3n del efecto de los\u00a0alimentos, la evaluaci\u00f3n de la penetraci\u00f3n del cerebro y los biomarcadores relacionados\u00a0con el receptor de PPAR Gamma.<\/p>\n<p>\u00abEs muy alentador ver que MIN-102 consigue modular el receptor PPAR gamma en el\u00a0sistema nervioso central a un nivel que no puede lograrse con las dosis aprobadas de\u00a0pioglitazona\u00bb, declara el Dr. Uwe Meya, CMO de Minoryx Therapeutics.<\/p>\n<p>Los resultados muestran que el MIN-102 es generalmente seguro y bien tolerado en exposiciones que exced\u00edan los niveles requeridos para la eficacia cl\u00ednica. No se observaron efectos adversos graves, y los efectos adversos leves han sido similares a los observados con el placebo. Los resultados de la penetraci\u00f3n cerebral y la evaluaci\u00f3n de biomarcadores confirmaron los resultados anteriores, mostrando que MIN-102 alcanza el sistema nervioso central y ejerce una amplia gama de efectos para tratar diversos aspectos de X-ALD, alineados con los observados en estudios precl\u00ednicos.\u00a0<\/p>\n<p>\u00abEstamos muy satisfechos con los resultados de la fase 1 del estudio, que nos\u00a0proporciona una base cient\u00edfica s\u00f3lida para planificar y realizar ensayos cl\u00ednicos\u00a0en pacientes que sufren X-ALD\u00bb destacat el Dr. Marc Martinell, CEO de Minoryx\u00a0Therapeutics.\u00a0<\/p>\n<p>A principios de a\u00f1o, el MIN-102, consigui\u00f3 la designaci\u00f3n de medicamento hu\u00e9rfano de la Agencia Europea de Medicamentos (<a href=\"http:\/\/www.pcb.ub.edu\/portal\/ca\/noticies\/-\/noticia\/not_el-min-102-de-minoryx-rep-la-designacio-de-medicament-orfe-de-l-ema?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dminoryx%26_cercador_WAR_empleatsempresesportlet_tab%3D3&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dminoryx%26_cercador_WAR_empleatsempresesportlet_tab%3D3\" target=\"_blank\" rel=\"noopener noreferrer\">EMA<\/a>) y de la Food and Drug Administration(<a href=\"http:\/\/www.pcb.ub.edu\/portal\/ca\/noticies\/-\/noticia\/not_el-min-102-de-minoryx-rep-la-designacio-de-medicament-orfe-de-l-fda?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dminoryx%26_cercador_WAR_empleatsempresesportlet_tab%3D3&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dminoryx%26_cercador_WAR_empleatsempresesportlet_tab%3D3\" target=\"_blank\" rel=\"noopener noreferrer\">FDA<\/a>). Bas\u00e1ndose en la conclusi\u00f3n exitosa del estudio de fase 1, Minoryx \u00a0iniciar\u00e1 pr\u00f3ximamente un ensayo de fase 2\/3.<\/p>\n<p>\n\u2022 <a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/noticies\/-\/noticia\/not_el-min-102-de-minoryx-rep-la-designacio-de-medicament-orfe-de-l-fda?inheritRedirect=false&amp;redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dminoryx%26_cercador_WAR_empleatsempresesportlet_tab%3D3&amp;backURL=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_cercador_WAR_empleatsempresesportlet_keywords%3Dminoryx%26_cercador_WAR_empleatsempresesportlet_tab%3D3\" target=\"_blank\" rel=\"noopener noreferrer\">Not\u00edcia relacionada [+]<\/a><\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"http:\/\/www.pcb.ub.edu\/portal\/es\/cerca?p_p_id=cercador_WAR_empleatsempresesportlet&amp;p_p_lifecycle=0&amp;p_p_state=maximized&amp;p_p_mode=view&amp;p_p_col_id=column-1&amp;p_p_col_count=1&amp;_cercador_WAR_empleatsempresesportlet_jspPage=%2Fhtml%2Fcommon%2Fdetall-empresa.jsp&amp;_cercador_WAR_empleatsempresesportlet_empresaId=ENT_006790&amp;_cercador_WAR_empleatsempresesportlet_redirect=%2Fportal%2Fca%2Fcerca%3Fp_p_id%3Dcercador_WAR_empleatsempresesportlet%26p_p_lifecycle%3D0%26p_p_mode%3Dview%26_cercador_WAR_empleatsempresesportlet_keywords%3Dminoryx%26_cercador_WAR_empleatsempresesportlet_tab%3D1\" target=\"_blank\" rel=\"noopener noreferrer\">Minoryx Therapeutics<\/a> \u2013especializada en el descubrimiento de nuevos f\u00e1rmacos para enfermedades hu\u00e9rfanas con sede en el Parc Cient\u00edfic\u00a0de Barcelona\u2013 ha completado con \u00e9xito el ensayo cl\u00ednico de fase 1 con el candidato a f\u00e1rmaco <a href=\"http:\/\/www.minoryx.com\/pipeline\/x-linked-adrenoleukodystrophy\/\" target=\"_blank\" rel=\"noopener noreferrer\">MIN-102<\/a>, enfocado a tratar la adrenoleucodistrofia ligada al cromosoma X (<a href=\"http:\/\/www.minoryx.com\/pipeline\/x-linked-adrenoleukodystrophy\/\" target=\"_blank\" rel=\"noopener noreferrer\">X-ALD<\/a>), una enfermedad rara, neurodegenerativa y potencialmente mortal, para la cual no hay ning\u00fan tratamiento farmacol\u00f3gico.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"author":1,"featured_media":26732,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"class_list":["post-39068","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sin-categorizar"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102 - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102 - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Minoryx Therapeutics \u2013especializada en el descubrimiento de nuevos f\u00e1rmacos para enfermedades hu\u00e9rfanas con sede en el Parc Cient\u00edfic\u00a0de Barcelona\u2013 ha completado con \u00e9xito el ensayo cl\u00ednico de fase 1 con el candidato a f\u00e1rmaco MIN-102, enfocado a tratar la adrenoleucodistrofia ligada al cromosoma X (X-ALD), una enfermedad rara, neurodegenerativa y potencialmente mortal, para la cual no hay ning\u00fan tratamiento farmacol\u00f3gico. \u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-22T23:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-16T15:22:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/03\/16049224305fa92c3ea5033.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"451\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102\",\"datePublished\":\"2017-03-22T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:22:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/\"},\"wordCount\":382,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/03\\\/16049224305fa92c3ea5033.jpeg\",\"articleSection\":[\"Sin categorizar\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/\",\"name\":\"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102 - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/03\\\/16049224305fa92c3ea5033.jpeg\",\"datePublished\":\"2017-03-22T23:00:00+00:00\",\"dateModified\":\"2020-11-16T15:22:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/03\\\/16049224305fa92c3ea5033.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2017\\\/03\\\/16049224305fa92c3ea5033.jpeg\",\"width\":800,\"height\":451},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102 - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/","og_locale":"es_ES","og_type":"article","og_title":"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102 - Parc Cient\u00edfic de Barcelona","og_description":"Minoryx Therapeutics \u2013especializada en el descubrimiento de nuevos f\u00e1rmacos para enfermedades hu\u00e9rfanas con sede en el Parc Cient\u00edfic\u00a0de Barcelona\u2013 ha completado con \u00e9xito el ensayo cl\u00ednico de fase 1 con el candidato a f\u00e1rmaco MIN-102, enfocado a tratar la adrenoleucodistrofia ligada al cromosoma X (X-ALD), una enfermedad rara, neurodegenerativa y potencialmente mortal, para la cual no hay ning\u00fan tratamiento farmacol\u00f3gico. \u00a0","og_url":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2017-03-22T23:00:00+00:00","article_modified_time":"2020-11-16T15:22:30+00:00","og_image":[{"width":800,"height":451,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/03\/16049224305fa92c3ea5033.jpeg","type":"image\/jpeg"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"adminpcb","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102","datePublished":"2017-03-22T23:00:00+00:00","dateModified":"2020-11-16T15:22:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/"},"wordCount":382,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/03\/16049224305fa92c3ea5033.jpeg","articleSection":["Sin categorizar"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/","url":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/","name":"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102 - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/03\/16049224305fa92c3ea5033.jpeg","datePublished":"2017-03-22T23:00:00+00:00","dateModified":"2020-11-16T15:22:30+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/03\/16049224305fa92c3ea5033.jpeg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2017\/03\/16049224305fa92c3ea5033.jpeg","width":800,"height":451},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/minoryx-completa-con-exito-el-ensayo-clinico-de-fase-1-para-min-102\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Minoryx completa con \u00e9xito el ensayo cl\u00ednico de fase 1 para MIN-102"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/39068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=39068"}],"version-history":[{"count":1,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/39068\/revisions"}],"predecessor-version":[{"id":45163,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/39068\/revisions\/45163"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/26732"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=39068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=39068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=39068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}